Navigation Links
Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for the First Quarter of Fiscal Year 2010
Date:11/16/2009

LAIYANG, China, Nov. 16 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc., (OTC Bulletin Board: JGBO; "Jiangbo" or the "Company"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced that the Company will host a conference call at 9:00 a.m. Eastern Time on Wednesday, November 18, 2009 to discuss financial results for its first quarter of fiscal year 2010.

Conference Call

Mr. Wubo Cao, Chairman and CEO, and Ms. Elsa Sung, CFO, will host the conference call.

To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: (800) 688 0796. International callers can dial (617) 614 4070. The conference passcode is 616 816 13.

If you are unable to participate in the call at that time, a replay of the conference call will be available from Wednesday, November 18, 2009 at 11:00 a.m. Eastern Time for 14 days. To access the replay, please call (888) 286 8010. International callers can dial (617) 801 6888. The conference replay passcode is 464 133 98.

About Jiangbo Pharmaceuticals, Inc.

Jiangbo Pharmaceuticals, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong province. Jiangbo is a major pharmaceutical company in China producing both western and Chinese herbal-based medical drugs in tablet, capsule, granule, and electuary (sticky syrup) form.

Safe Harbor Statement

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

    For more information, please contact:

    Company Contact:
     Ms. Elsa Sung, CFO
     Jiangbo Pharmaceuticals, Inc.
     Tel:   +1-954-727-8435
     Email: elsasung@jiangbo.com
     Web:   http://www.jiangbopharma.com/

    Investor Relations Contact:
     Mr. Crocker Coulson, President
     CCG Investor Relations
     Email: crocker.coulson@ccgir.com
     Tel:   +1-646-213-1915 (NY office)
     Web:   http://www.ccgirasia.com

SOURCE Jiangbo Pharmaceuticals, Inc.


'/>"/>
SOURCE Jiangbo Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results
2. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
4. Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results
5. BioMarin Acquires Huxley Pharmaceuticals, Inc.
6. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
7. Rib-X Pharmaceuticals, Inc. Co-Founder, Thomas A. Steitz, Ph.D., Awarded the 2009 Nobel Prize in Chemistry
8. Biostar Pharmaceuticals, Inc. Receives the Chinese Military Drug Administration Clearance to Begin Clinical Trial for Zushima Analgesic Aerosol Spray
9. Biostar Pharmaceuticals, Inc. Receives Patent for Aoxing Ganbao
10. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
11. Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Conn. , Feb. 16, 2017 The Lockwood ... the 2017 Best Place to Work in Connecticut ... This is the third year in a row that Lockwood ... this year to earn the number-two spot in 2017. The ... maintaining workplace excellence. The winners were determined through a survey ...
(Date:2/16/2017)... Feb. 16, 2017  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... focused on the development and commercialization of innovative ... announced that Vincent J. Angotti has ... of the company,s board of directors, effective Monday, ... decades of experience leading executive and commercial teams ...
(Date:2/16/2017)... SCOTTSDALE, Ariz. , Feb. 16, 2017 HealthInfoNet ... announced today it is partnering with Orion Health on the ... of all Maine residents, clinical information ... hospitals and over 500 ambulatory care sites. Pending ... deploy Orion Health,s Amadeus , a precision medicine platform ...
Breaking Medicine Technology:
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... (ISTS) brings its educational assistance management solution to the exhibit floor for the ... in Orlando, Fla. , From Feb. 19–23, 2017, more than 40,000 healthcare ...
(Date:2/17/2017)... ... February 17, 2017 , ... Qualis Health, one of ... the 8th Annual DecisionHealth Platinum Awards in recognition of its innovative healthcare management ... recognized across multiple award categories, highlighting four of the organization’s current programs:, ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... clinical operations executives and focusing on all facets of clinical trial planning and ... management , patient engagement, and more. In addition, attendees stopping by Pharmica’s booth ...
(Date:2/17/2017)... , ... February 17, 2017 , ... Top neuroendocrine cancer ... Healing NET Foundation Summit from February 21 - 23 in Beaver Creek, CO. It ... This marks the Summit’s second year in Beaver Creek, hosting over 60 faculty members ...
(Date:2/16/2017)... ... 17, 2017 , ... For some cancer survivors, the memories ... Physician researchers at The Marcus Institute of Integrative Health at Thomas Jefferson ... reducing symptoms of traumatic stress in cancer patients and published their results ...
Breaking Medicine News(10 mins):